blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3052122

EP3052122 - COMBINATION TUMOR TREATMENT WITH DRUG-LOADED, BISPECIFIC LIGAND-TARGETED MINICELLS AND INTERFERON-GAMMA [Right-click to bookmark this link]
StatusGrant of patent is intended
Status updated on  14.04.2024
Database last updated on 27.07.2024
FormerExamination is in progress
Status updated on  16.03.2018
Most recent event   Tooltip14.04.2024New entry: Communication of intention to grant a patent 
Applicant(s)For all designated states
EnGeneIC Molecular Delivery Pty Ltd
Building 2, 25 Sirius Road
Lane Cove West
Sydney, NSW 2066 / AU
[2024/20]
Former [2016/32]For all designated states
EnGeneIC Molecular Delivery Pty Ltd.
Building 2, 25 Sirius Road Lane Cove West
Sydney NSW 2066 / AU
Inventor(s)01 / BRAHMBHATT, Himanshu
c/o Engeneic Molecular Delivery Pty Ltd.
Building 2
25 Sirius Road
Lane Cove West
Sydney, New South Wales 2066 / AU
02 / MACDIARMID, Jennifer
c/o Engeneic Molecular Delivery Pty Ltd.
Building 2
25 Sirius Road
Lane Cove West
Sydney, New South Wales 2066 / AU
 [2016/32]
Representative(s)Altmann Stößel Dick Patentanwälte PartG mbB
Theodor-Heuss-Anlage 2
68165 Mannheim / DE
[N/P]
Former [2016/32]Herzog, Fiesser & Partner Patentanwälte PartG mbB
Patentanwälte
Dudenstrasse 46
68167 Mannheim / DE
Application number, filing date14851383.103.10.2014
[2016/32]
WO2014IB02824
Priority number, dateUS201361887258P04.10.2013         Original published format: US 201361887258 P
[2016/32]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015049589
Date:09.04.2015
Language:EN
[2015/14]
Type: A1 Application with search report 
No.:EP3052122
Date:10.08.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 09.04.2015 takes the place of the publication of the European patent application.
[2016/32]
Search report(s)International search report - published on:KR09.04.2015
(Supplementary) European search report - dispatched on:EP21.04.2017
ClassificationIPC:A61K38/21, A61K48/00, A61P35/00, A61K39/395, A61K31/704, A61K35/74, A61K45/06, C07K16/28, C07K16/44
[2017/20]
CPC:
A61K31/704 (EP,EA,IL,MX,US); A61K38/217 (EP,EA,IL,MX,US); A61K39/44 (EA,IL,US);
A61K35/74 (EP,EA,IL,US); A61K39/3955 (EP,EA,IL,US); A61K39/39583 (EP,EA,IL,US);
A61K45/06 (EP,EA,IL,US); A61K48/00 (IL,MX); A61P35/00 (EP);
A61P43/00 (EP); C07K16/2863 (EP,EA,IL,US); C07K16/44 (EP,EA,IL,US);
C07K2317/31 (EP,EA,US) (-)
C-Set:
A61K31/704, A61K2300/00 (EP,US);
A61K35/74, A61K2300/00 (US,EP);
A61K38/217, A61K2300/00 (US,EP);
A61K39/3955, A61K2300/00 (EP,US);
A61K39/39583, A61K2300/00 (US,EP)
(-)
Former IPC [2016/32]A61K38/21, A61K48/00, A61P35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/32]
Extension statesBA26.04.2016
ME26.04.2016
TitleGerman:KOMBINATIONSTUMORBEHANDLUNG MIT ARZNEIMITTELGELADENEN, BISPEZIFISCHEN, LIGANDENGEZIELTEN MINIZELLEN UND INTERFERON-GAMMA[2016/32]
English:COMBINATION TUMOR TREATMENT WITH DRUG-LOADED, BISPECIFIC LIGAND-TARGETED MINICELLS AND INTERFERON-GAMMA[2016/32]
French:TRAITEMENT DE TUMEUR COMBINÉ AVEC MINICELLULES CHARGÉES DE MÉDICAMENT DIRIGÉES PAR LIGANDS BISPÉCIFIQUES ET INTERFÉRON GAMMA[2016/32]
Entry into regional phase26.04.2016National basic fee paid 
26.04.2016Search fee paid 
26.04.2016Designation fee(s) paid 
26.04.2016Examination fee paid 
Examination procedure26.04.2016Examination requested  [2016/32]
14.11.2017Amendment by applicant (claims and/or description)
14.03.2018Despatch of a communication from the examining division (Time limit: M04)
24.07.2018Reply to a communication from the examining division
10.09.2018Despatch of a communication from the examining division (Time limit: M04)
24.09.2018Reply to a communication from the examining division
06.02.2019Despatch of a communication from the examining division (Time limit: M04)
17.06.2019Reply to a communication from the examining division
09.10.2019Despatch of a communication from the examining division (Time limit: M04)
17.02.2020Reply to a communication from the examining division
15.10.2020Despatch of a communication from the examining division (Time limit: M06)
19.04.2021Reply to a communication from the examining division
21.05.2021Despatch of a communication from the examining division (Time limit: M04)
15.09.2021Reply to a communication from the examining division
18.10.2022Despatch of a communication from the examining division (Time limit: M04)
08.02.2023Reply to a communication from the examining division
15.04.2024Communication of intention to grant the patent
Fees paidRenewal fee
21.10.2016Renewal fee patent year 03
25.10.2017Renewal fee patent year 04
24.10.2018Renewal fee patent year 05
25.10.2019Renewal fee patent year 06
23.10.2020Renewal fee patent year 07
25.10.2021Renewal fee patent year 08
25.10.2022Renewal fee patent year 09
25.10.2023Renewal fee patent year 10
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[Y]WO2013088250  (ENGENEIC MOLECULAR DELIVERY PTY LTD [AU]);
International search[X]WO2005056749  (ENGENEIC MOLECULAR DELIVERY PTY LTD [AU], et al);
 [X]WO2006021894  (ENGENEIC GENE THERAPY PTY LTD [AU], et al);
 [X]US2011275585  (BRAHMBHATT HIMANSHU [AU], et al);
 [A]  - MACDIARMID ET AL., "Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics", CANCER CELL, (2007), vol. 11, no. 5, pages 431 - 445, XP002507684

DOI:   http://dx.doi.org/10.1016/J.CCR.2007.03.012
 [A]  - MACDIARMID ET AL., "Bacterially-derived nanocells for tumor-targeted delivery of chemotherapeutics and cell cycle inhibitors", CELL CYCLE, (2007), vol. 6, no. 17, pages 2099 - 2105, XP002635365

DOI:   http://dx.doi.org/10.4161/cc.6.17.4648
by applicantWO9802446
 WO0067776
 WO03033519
 WO2004113507
 WO2005056749
 WO2005079854
 US7183105
 US2007237744
 WO2008012695
 US2008038296
 US2008051469
 WO2009027830
 US8470984
 US8591862
    - WANG, "The antiproliferative activity of combination treatment of IFN-gamma and doxorubicin on H22 cells: in vitro and in vivo", Asian Journal of Pharmaceutical Sciences, (20090000), pages 277 - 282, XP055362257
    - KLOKE et al., Eur. J. Haematol., (19920000), vol. 48, pages 93 - 8
    - WANDL et al., Semin. Oncol., (19920000), vol. 19, pages 88 - 94
    - LEMMON; SCHLESSINGER, Cell, (20100000), vol. 141, pages 1117 - 134
    - RICE et al., Semin. Nucl. Med., (20110000), vol. 41, pages 265 - 282
    - CLARK-CURTISS; CURTISS, Methods Enzymol., (19830000), vol. 101, pages 347 - 362
    - TANPURE et al., Bioorg. Med. Chem., (20130000), vol. 21, pages 8019 - 32
    - OKANO et al., J. Am. Chem. Soc., (20060000), vol. 128, pages 7136 - 37
    - KHALIL et al., Proc Nat'l Acad. USA, (20090000), vol. 106, pages 11667 - 72
    - MACDIARMID et al., Nature Biotech., (20090000), vol. 27, pages 645 - 51
    - OH; PARK, Advanced Drug Delivery Rev., (20090000), vol. 61, pages 850 - 62
    - KOTA et al., Cell, (20090000), vol. 137, pages 1005 - 17
    - TAKESHITA et al., Molec. Ther., (20100000), vol. 18, pages 181 - 87
    - CHU et al., PLoS Biology, (20060000), vol. 4, pages 1122 - 36
    - GREGORY et al., Methods in Molecular Biology, (20060000), vol. 342, pages 33 - 47
    - SIOUD, Trends Pharmacol. Sci., (20040000), vol. 25, pages 22 - 8
    - CAPLEN, Expert Opin. Biol. Ther., (20030000), vol. 3, pages 575 - 86
    - NIETH et al., FEBS Lett., (20030000), vol. 545, pages 144 - 50
    - CAPLEN; MOUSSES, Ann. NY Acad. Sci., (20030000), vol. 1002, pages 56 - 62
    - DUXBURY et al., Ann. Surg., (20040000), vol. 240, pages 667 - 74
    - YAGUE et al., Gene Ther., (20040000), vol. 11, pages 1170 - 74
    - DUAN et al., Mol. Cancer Ther., (20040000), vol. 3, pages 833 - 8
    - D'ANGIOLELLA et al., Cell, (20120000), vol. 149, pages 1023 - 34
    - IFTODE et al., Crit. Rev. Biochem. Mol. Biol., (19990000), vol. 34, pages 141 - 80
    - DE BOER et al., J. Bacteriol., (19920000), vol. 174, no. 1, pages 63 - 70
    - RASKIN; DE BOER, J. Bacteriol., (19990000), vol. 181, pages 6419 - 6424
    - HU; LUTKENHAUS, Mol. Microbio., (19990000), vol. 34, no. 1, pages 82 - 90
    - HARRY, Mol. Microbiol., (20010000), vol. 40, no. 4, pages 795 - 803
    - REEVE; CORNETT, J. Virol., (19750000), vol. 15, pages 1308 - 16
    - BRITTON et al., Genes Dev., (19980000), vol. 12, pages 1254 - 9
    - IRETON et al., J. Bacteriol., (19940000), vol. 176, pages 5320 - 29
    - HIRAGA et al., J. Bacteriol., (19890000), vol. 171, pages 1496 - 1505
    - STEWART; D'ARI, J. Bacteriol., (19920000), vol. 174, pages 4513 - 6
    - OKADA et al., J. Bacteriol., (19940000), vol. 176, pages 917 - 22
    - B ' MANUAL OF SYSTEMATIC BIOLOGY
    - GOH; SORKIN, Cold Spring Harb. Perspect. Biol., (20130000), vol. 5, page a017459
    - LEMMON; SCHLESSINGER, Cell, (20100000), vol. 141, no. 7, pages 1117 - 134
    - CARAVELLA; LUGOVSKOY, Curr. Opin. Chem. Biol., (20100000), vol. 14, pages 520 - 28
    - WYKOSKY et al., Clin Cancer Res., (20080000), vol. 14, pages 199 - 208
    - JARBOE et al., Cancer Res., (20070000), vol. 67, pages 7983 - 86
    - DEBINSKI et al., J. Neurooncol., (20000000), vol. 48, pages 103 - 11
    - HERSHEY, J. Allergy Clin. Immunol., (20030000), vol. 111, pages 677 - 90
    - DEBINSKI; GIBO, Mol. Med., (20000000), vol. 6, pages 440 - 49
    - DA SILVA et al., Breast Cancer Res., (20100000), vol. 12, no. R46, pages 1 - 13
    - GALL et al., Protein Engineering, Design and Selection, (20040000), vol. 17, pages 357 - 66
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.